S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer

Bibliographic Details
Main Authors:	Feiyu Diao, Wei Lai, Zhonghua Chu
Format:	Article
Language:	English
Published:	Wiley 2019-10-01
Series:	Cancer Communications
Online Access:	http://link.springer.com/article/10.1186/s40880-019-0408-2

Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
by: Noriyuki Hirahara, et al.
Published: (2021-10-01)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
by: Wu X, et al.
Published: (2021-02-01)

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China
by: Birendra Kumar Sah, et al.
Published: (2021-01-01)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01)

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin
by: Mozaffar Aznab, et al.
Published: (2020-07-01)

Concurrent chemoradiotherapy with low-dose weekly docetaxel followed by consolidation chemotherapy with docetaxel and cisplatin in the treatment of stage III non-small cell lung cancer
by: Tianlin XIAO, et al.
Published: (2008-02-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
by: Tsuneo Shimokawa, et al.
Published: (2021-01-01)

Effect of docetaxel + oxaliplatin + S-1 and docetaxel + cisplatin + fluorouracil on treatment of advanced gastric cancer
by: Wei Li, et al.
Published: (2016-09-01)

Review of docetaxel in the treatment of gastric cancer
by: Eric D Tetzlaff, et al.
Published: (2008-09-01)

Effects of docetaxel combined with platinum drugs and S-1 chemotherapy on cancer cell growth in advanced gastric cancer lesions
by: Xiong Zhang, et al.
Published: (2017-06-01)

Effect of the preoperative docetaxel combined with S-1 chemotherapy on the oncogene expression in advanced gastric cancer lesion
by: E-Yi Ben, et al.
Published: (2017-11-01)

Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
by: Xiao-Long Chen, et al.
Published: (2013-01-01)

Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma
by: Gaurav Goel, et al.
Published: (2010-04-01)

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
by: Zuo Fei, et al.
Published: (2019-04-01)

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report
by: Hideyuki Niwa, et al.
Published: (2018-01-01)

Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery
by: Liu Y, et al.
Published: (2016-03-01)

Cisplatin plus Docetaxel Chemotherapy for Thoracic Lymph Node Metastasis from Cancer of Unknown Primary – Experience of Three Cases
by: Takashi Kobayashi, et al.
Published: (2009-05-01)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
by: Ying Liu, et al.
Published: (2013-01-01)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
by: Zhang Y, et al.
Published: (2021-03-01)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
by: Zhang MM, et al.
Published: (2016-06-01)

A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
by: Tie Zhou, et al.
Published: (2015-01-01)

The relationship between platelet–lymphocyte ratio, neutrophil–lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience
by: Mutlu Dogan, et al.
Published: (2015-01-01)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
by: Kim Dong-Wan, et al.
Published: (2007-11-01)

Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis
by: Yuji Akiyama, et al.
Published: (2018-07-01)

Adjuvant Chemotherapy for Stage III Colon Cancer
by: Julien Taieb, et al.
Published: (2020-09-01)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
by: Xin Yao, Janet Hosenpud, Christopher R. Chitambar, John Charlson, Yee Chung Cheng
Published: (2012-01-01)

Docetaxel, oxaliplatin and S-1 in neoadjuvant chemotherapy of markers, angiogenesis and cell invasion of advanced gastric cancer patients with tumor molecular
by: Hao Yu, et al.
Published: (2018-01-01)

Periungual lesions secondary to chemotherapy with docetaxel
by: Dawid Sigorski, et al.
Published: (2020-02-01)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
by: Prestwich Robin, et al.
Published: (2011-06-01)

Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India
by: K Govind Babu, et al.
Published: (2018-01-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
by: Wu P, et al.
Published: (2018-10-01)

Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer
by: Keiji Nishibeppu, et al.
Published: (2018-01-01)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
by: Jang Ho Cho, et al.
Published: (2017-01-01)

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
by: Yokoi T, et al.
Published: (2012-05-01)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
by: Xin Zhang, et al.
Published: (2021-07-01)

Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis
by: Tang C, et al.
Published: (2020-12-01)

S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer

Similar Items

Similar Items